Cargando…

Mesothelin-targeted immunotoxin RG7787 has synergistic anti-tumor activity when combined with taxanes

Recombinant immunotoxins (RITs) are antibody-based therapeutics that carry a toxin payload. The RG7787 RIT targets the cancer antigen mesothelin to deliver a recombinantly-engineered, reduced immunogenicity variant of Pseudomonas exotoxin A (PE) to the cytosol where it inhibits protein synthesis. He...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kolyvas, Emily, Rudloff, Michael, Poruchynsky, Marianne, Landsman, Rebekah, Hollevoet, Kevin, Venzon, David, Alewine, Christine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5354724/ https://www.ncbi.nlm.nih.gov/pubmed/27999204 http://dx.doi.org/10.18632/oncotarget.13984

Ejemplares similares

Combining anti-CTLA4 with RG7787, an immunotoxin targeting mesothelin, promotes tumor eradication
por: Leshem, Jasmin, et al.
Publicado: (2015)

Protein Synthesis Inhibition Activity of Mesothelin Targeting Immunotoxin LMB-100 Decreases Concentrations of Oncogenic Signaling Molecules and Secreted Growth Factors
por: El-Behaedi, Salma, et al.
Publicado: (2018)

Mesothelin-Targeted Recombinant Immunotoxins for Solid Tumors
por: Hagerty, Brendan L., et al.
Publicado: (2020)

Methylation-Associated Partial Down-Regulation of Mesothelin Causes Resistance to Anti-Mesothelin Immunotoxins in a Pancreatic Cancer Cell Line
por: Hollevoet, Kevin, et al.
Publicado: (2015)

Low serum mesothelin in pancreatic cancer patients results from retention of shed mesothelin in the tumor microenvironment
por: Zhang, Xianyu, et al.
Publicado: (2022)

Dual B- and T-cell de-immunization of recombinant immunotoxin targeting mesothelin with high cytotoxic activity
por: Mazor, Ronit, et al.
Publicado: (2016)

Combination Treatments with the PKC Inhibitor, Enzastaurin, Enhance the Cytotoxicity of the Anti-Mesothelin Immunotoxin, SS1P
por: Mattoo, Abid R., et al.
Publicado: (2013)

Anti-mesothelin immunotoxin induces mesothelioma eradication, anti-tumor immunity, and the development of tertiary lymphoid structures
por: Liu, Wenlong, et al.
Publicado: (2022)

Protection of the Furin Cleavage Site in Low-Toxicity Immunotoxins Based on Pseudomonas Exotoxin A
por: Kaplan, Gilad, et al.
Publicado: (2016)

Quantification of recombinant immunotoxin delivery to solid tumors allows for direct comparison of in vivo and in vitro results
por: Mason-Osann, Emily, et al.
Publicado: (2015)

Systemic immune changes accompany combination treatment with immunotoxin LMB‐100 and nab‐paclitaxel
por: Pegna, Guillaume Joe, et al.
Publicado: (2022)

Synergistic immunotoxin-paclitaxel combination against lymphoma
por: Müller, Fabian
Publicado: (2017)

Pharmacokinetic behaviour of the chemoprotectants BNP7787 and mesna after an i.v. bolus injection in rats
por: Verschraagen, M, et al.
Publicado: (2004)

Cysteine Specific Targeting of the Functionally Distinct Peroxiredoxin and Glutaredoxin Proteins by the Investigational Disulfide BNP7787
por: Parker, Aulma R., et al.
Publicado: (2015)

Synergistic anti-cancer effects of immunotoxin and cyclosporin in vitro and in vivo
por: Andersson, Y, et al.
Publicado: (2009)

Megakaryocytic Potentiating Factor and Mature Mesothelin Stimulate the Growth of a Lung Cancer Cell Line in the Peritoneal Cavity of Mice
por: Zhang, Jingli, et al.
Publicado: (2014)

Phase I and pharmacokinetic study of the novel chemoprotector BNP7787 in combination with cisplatin and attempt to eliminate the hydration schedule
por: Boven, E, et al.
Publicado: (2005)

High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis
por: Thomas, Anish, et al.
Publicado: (2015)

Mesothelin-Specific Immune Responses and Targeted Immunotherapy for Mesothelin-Expressing Tumors
por: Einama, Takahiro, et al.
Publicado: (2017)

Synergistic Anticancer Effects of the 9.2.27PE Immunotoxin and ABT-737 in Melanoma
por: Risberg, Karianne, et al.
Publicado: (2011)

Phase I and pharmacologic study of BNP7787, a novel chemoprotector in patients with advanced non-small cell lung cancer
por: Masuda, Noriyuki, et al.
Publicado: (2010)

Novel covalent modification of human anaplastic lymphoma kinase (ALK) and potentiation of crizotinib-mediated inhibition of ALK activity by BNP7787
por: Parker, Aulma R, et al.
Publicado: (2015)

Immunotoxins: experimental design
por: Dall, P, et al.
Publicado: (2001)

Immunotoxins: The Role of the Toxin (†)
por: Antignani, Antonella, et al.
Publicado: (2013)

Countering immunotoxin immunogenicity
por: Flavell, David J
Publicado: (2016)

DZ-2384 has a superior preclinical profile to taxanes for the treatment of triple-negative breast cancer and is synergistic with anti-CTLA-4 immunotherapy
por: Bernier, Cynthia, et al.
Publicado: (2018)

Targeting mesothelin in ovarian cancer
por: Ghafoor, Azam, et al.
Publicado: (2018)

Liver myofibroblasts of murine origins express mesothelin: Identification of novel rat mesothelin splice variants*
por: Fausther, Michel, et al.
Publicado: (2017)

Mesothelin-targeted second generation CAR-T cells inhibit growth of mesothelin-expressing tumors in vivo
por: Ye, Lin, et al.
Publicado: (2019)

Highly active CAR T cells that bind to a juxtamembrane region of mesothelin and are not blocked by shed mesothelin
por: Liu, Xiufen, et al.
Publicado: (2022)

An engineered T-cell engager with selectivity for high mesothelin-expressing cells and activity in the presence of soluble mesothelin
por: Snell, Daniel, et al.
Publicado: (2023)

Interactions Between Pseudomonas Immunotoxins and the Plasma Membrane: Implications for CAT-8015 Immunotoxin Therapy
por: Bokori-Brown, Monika, et al.
Publicado: (2018)

Treatment of solid tumors with immunotoxins
por: Messmer, Davorka, et al.
Publicado: (2005)

Bouganin, an Attractive Weapon for Immunotoxins
por: Bortolotti, Massimo, et al.
Publicado: (2018)

Immunotoxin Therapy for Lung Cancer
por: Xie, Li-Yi, et al.
Publicado: (2017)

The hen model of human ovarian cancer develops anti-mesothelin autoantibodies in response to mesothelin expressing tumors
por: Yu, Yi, et al.
Publicado: (2011)

Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer
por: Zanjirband, Maryam, et al.
Publicado: (2017)

Modulating Mesothelin Shedding to Improve Therapy
por: Zhang, Yujian, et al.
Publicado: (2012)

Mesothelin as a biomarker for targeted therapy
por: Lv, Jiang, et al.
Publicado: (2019)

Adjuvant therapy of endometrial cancer: “taxane or not taxane, this is the question”
por: Lorusso, Vito, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_sravcm70elliafu9atos6o9p82